Furthermore, in our analysis publicly available genomic data on 1280 HCC samples, we found that CDKN2A alterations, like KMT2C alterations, showed significant co-occurrence with MYC gains and amplifications. Here, CDKN2A is linked to hepatocellular carcinoma.